Jared Kaltwasser

Altered microbiota and inflammation associated with irritable bowel disease (IBD) appear to make it more difficult for patients to fight off Clostridioides difficile infection, according to a recent study.

The more often a patient used systemic corticosteroids, the higher their risk of moderate or severe COVID-19 and all-cause mortality, the study found.

No clinical or genetic markers were found to be predictive of psoriatic arthritis in patients with psoriasis, but one laboratory marker was identified.

Touching one’s face can heighten infection risk, but it may also help protect the body by fostering microbial diversity, according to a recent study.

Exome sequencing of patients with kidney disease and their families identified 17 different monogenetic causes of kidney disease.

The development of a successful gene therapy for RPE65-associated inherited retinal disease is a major breakthrough, but it also prompts difficult questions about which patients are good candidates for the therapy.

The new report may help explain why patients with psoriasis have a higher risk of cardiovascular problems.

New research based on real-world data largely aligns with the scientific literature, although one monoclonal antibody—dupilumab—stood out for its very low risk.

A new review shows secukinumab continued to have a strong safety profile after 6 years on the market.

Considerable evidence shows sodium-glucose co-transporter-2 inhibitors have cardioprotective benefits, but new research elucidates the ways in which the drugs can also have positive renal impacts.

New data suggest a microbiota-based therapy can reduce C diff recurrence in patients where donor microbiota and patient microbiota successfully converge.

A new analysis may give clinicians a more in-depth understanding of an individual patient’s multiple sclerosis (MS) disease course.

A systematic review found significant evidence supporting self-management interventions for inflammatory arthritis, but also found it was difficult to draw conclusions about specific types of programs.

A new meta-analysis finds rigorous evidence lacking; however, existing data suggest preservative-free formulations of beta-blockers may work just as well as preserved beta-blockers in reducing intraocular pressure.

A new report suggests patients with persistent nail psoriasis may benefit from biologics like tildrakizumab.

A handful of systemic therapies can be prescribed off label to effectively treat atopic dermatitis (AD), but investigators said a biologic option may be best for many patients.

Although existing research has shown structural differences between multiple sclerosis (MS) and neuromyelitis optica spectrum disorder in following optic neuritis, the new report also covers non–optic neuritis eyes.

Alcohol abuse, obesity, and the use of systemic therapies instead of biologics were all linked with poor response among individuals with psoriasis.

Clinical trials and postmarketing surveillance suggest secukinumab has a favorable safety profile and low rates of discontinuation. A new study evaluated those metrics in a real-world setting in axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA).

Both sets of data were unveiled at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which was held earlier this month in a virtual format.

The analysis identified 4 genes that were driven by atopic dermatitis (AD) and which had significant expression changes in favor of MDD development.

The report gives a more holistic picture of a highly studied by little understood issue in multiple sclerosis.

Three biologics appeared to increase herpes zoster risk, but 2 other therapies were shown to lower the risk, according to a study of patients in a Taiwanese national database.

About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital.

Older patients with chronic kidney disease face higher risks of intensive care unit admission and in-hospital mortality if they contract COVID-19, a new report shows.

Individuals with insomnia had 1.41 times the risk of developing hypertension, compared with people without the sleep disorder.

Patients with atopic dermatitis (AD) benefit from extensive patient education. A new report suggests group-based sessions are preferred to individual educational sessions or fun activities.

Existing research has focused on skin symptoms, but a new study looks for alterations in the blood associated with moderate-to-severe atopic dermatitis.

The new study identified altered microRNA (miRNA) in gray matter lesions, which could provide a new important marker of multiple sclerosis (MS) progression.

About 5.4% of patients with end-stage renal disease (ESRD) who begin renal replacement therapy as children go on to have vascular events, and 4.1% of those patients die as a result of vascular events, though the real incidence rates are likely higher, according to new research.